Skip to content
OpenCapital
Get started

Boston Scientific BSX Cash & Equivalents

Cash & Equivalents at other companies

Abbott logo
AbbottABT
$5.1B-26.6%
TFX
TeleflexTFX
$329.55M+16.8%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$20.42B+9.9%
Stryker logo
StrykerSYK
$3.39B+42.8%
Haemonetics logo
HaemoneticsHAE
$245.44M-20.0%
CONMED logo
CONMEDCNMD
$37.33M+10.0%

Other financials

Income statement

See full
Revenue$5.4B+7.5%
Gross profit$3.8B+12.4%
Operating income$1.2B+43.8%
Net income$907.0M+14.1%
EPS (diluted)$0.61+15.1%

Balance sheet

See full
Total debt$659.0M-94.1%
Total equity$25.9B+16.4%
Total assets$44.4B+10.5%

Cash flow

See full
Operating cash flow$348.0M-35.7%
CapEx$177.0M-5.3%
Free cash flow$171.0M-51.7%

Valuation

See full
Market cap$68.43B-56.7%
P/E18.6×-44.6×
P/S3.3×-5.3×

Profitability

See full
Gross margin69.9%+1.7pp
Operating margin19.8%+2.8pp
Net margin17.5%+4.0pp
FCF margin16.9%-0.3pp

Returns & leverage

See full
Return on equity14.8%+5.2pp
Debt / equity0×-0.5×
Current ratio1.9×+0.4×

Where this comes from

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept us-gaap:Cash.

The official record: Boston Scientific’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Boston Scientific's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Boston Scientific's cash & equivalents?
Boston Scientific (BSX) reported cash & equivalents of $850M in Q1 2026.
How has Boston Scientific's cash & equivalents changed year-over-year?
Boston Scientific's cash & equivalents increased by 146.4% year-over-year, from $345M to $850M.
What is the long-term trend for Boston Scientific's cash & equivalents?
Over 5 years (2020 to 2025), Boston Scientific's cash & equivalents has grown at a 45.1% compound annual growth rate (CAGR), from $150M to $965M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.